Most Recent Articles by Anna Olechowska
Researchers assessed whether current metabolic parameters are inversely associated with cognitive functioning.
Reducing basal insulin delivery by 50%-80% 90 minutes before aerobic exercise better prevents hypoglycemia risk vs basal suspension or disconnection at exercise onset.
Menopausal hormone therapy may slow cognitive decline in postmenopausal women with mild cognitive impairment.
Romosozumab increased bone mineral density in postmenopausal women through increased bone formation and decreased bone resorption.
A recent study supports the clinical use of a combination of fasting glucose and HbA1c levels from a single blood sample to identify undiagnosed diabetes.
More Articles by Anna Olechowska
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally